Editorial: Exploring adaptive immunity in ruminants and humans: a one health perspective

社论:探索反刍动物和人类的适应性免疫:一体化健康视角

阅读:2

Abstract

Short-term boosting of the currently licensed rVSV∆G-ZEBOV-GP vaccine does not generate lasting antibody respones to Ebola virus (EBOV), prompting interest in strategies that elicit more durable immunity. Here, we elucidated the longitudinal humoral immune repertoire over 3 years following prime and boost rVSV∆G-ZEBOV-GP vaccinations administered 18 months apart in healthy adults compared to participants randomized to no boost. This delayed booster vaccination induced long-lasting EBOV-neutralizing antibodies that persisted up to 36 month at levels similar to peak titers after a single dose. Phage display libraries, expressing linear and conformational epitopes of EBOV glycoprotein (GP), demonstrated a highly diverse and durable antibody epitope repertoire following prime boost vaccination. Delayed booster vaccination recalled memory B cells, promoted anti-GP IgG class switching and induced antibodies specific to GP with Fcγ receptor interaction and functional antibody-dependent cellular cytotoxicity and phagocytosis. The 18-month interval led to 13-fold higher antibody affinity maturation than a single dose, maintained up to 36 months. Overall, delayed rVSV∆G-ZEBOV-GP booster vaccination promoted a diverse, stronger, durable, predominant IgG, highly affinity-matured antibody response to GP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。